NOT SO INNOCENT INDAPAMIDE

Authors

  • Shayan Aziz Diabetes and endocrine department, Chorley and South Ribble District General Hospital, Lancashire Teaching Hospitals
  • Abdullah Department of Cardiology, Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust (Blackpool Victoria Hospital), Whinney Heys Road, Blackpool, Lancashire, United Kingdom. FY3 9NR
  • Rajbhandari Diabetes and Endocrine Department, Chorley and South Ribble District General Hospital, Lancashire Teaching Hospitals

DOI:

https://doi.org/10.55519/JAMC-02-10426

Keywords:

indapamide, hyponatremia, neutropenia

Abstract

A 58-year-old asymptomatic man was referred by his general practitioner for abnormal blood results. Routine blood tests to monitor blood count and kidney functions showed neutropenia and hyponatremia. He was euvolemic on examination. Further detailed investigation did not reveal any cause of neutropenia and hyponatremia. After careful assessment of drug history, it transpired he recently started Indapamide for uncontrolled hypertension. Hyponatraemia is a common side effect of Indapamide and in addition, it can rarely cause agranulocytosis and leukopenia. Indapamide was stopped and the blood counts started to improve and became normal after two weeks.

References

Kuderer N, Dale D, Crawford J, Cosler L, Lyman G. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106(10):2258–66.

Dale DC. How I diagnose and treat neutropenia. Curr Opin Hematol 2017;12(1)1–4.

Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood 2014;124(8):1251–8.

National Institute for Health and Care Excellence. Hypertension in adults: Diagnosis and management. NICE guideline No.136. [Internet]. [cited 2021 Nov 18]. Available from: https://www.nice.org.uk/guidance/ng136

Audi S, Burrage D, Lonsdale D, Pontefract S, Coleman J, Hitchings A, et al. The top100 drugs and classes in England: an updated starter formulary for trainee prescribers. Br J Clin Pharmacol 2018;84(11):2562–71.

Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984;28(3):189–235.

Vukovich RA, Zisblatt M, Caruso F, Losi M, Barton J, Schotz WE, et al. Multi-centre clinical investigation of indapamide in the United States: a review. Curr Med Res Opon 1983;8(suppl 3):109–22.

Joint Formulary Committee. British National formulary. 82. London. BMJ group and Pharmaceutical Press; 2021. [Internet]. [cited 2021 Nov 18]. Available form: https://bnf.nice.org.uk/drug/indapamide.html1

Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol 2016;13(2):175–82.

Chiren MB, Rubin IL. Agranulocytosis secondary to hydrochlorothiazide therapy. Report of a case. JAMA 1962;181:54–5.

Additional Files

Published

2023-04-17